Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
What bowel dose constraint do you recommend if you are boosting a pelvic lymph node for prostate cancer?
Do you have a maximum bowel dose constraint?
Answer from: Radiation Oncologist at Community Practice
We generally use 55 Gy to < 5 cc based on Gyne literaturem and try to make sure the high prescribed dose is limited to one wall of bowel loop.
Comments
Radiation Oncologist at Torrance Memorial Medical Center
@Sushil Beriwal, could you share a paper or protoc...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
This is the one I was referring to. It’s a s...
2752
2753
Sign In
or
Register
to read more
Answer from: Radiation Oncologist at Academic Institution
60 to 66 Gy at 2 Gy per fraction.
Sign In
or
Register
to read more
6526
6532
Related Questions
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
How would you optimally boost patients with high or very high risk prostate cancer receiving definitive radiotherapy in 2025?
Should a patient who requires definitive treatment for prostate cancer as a pre-transplant requirement be strictly required to complete their course prior to transplant/initiation of immunosuppression?
Given the different rates of testosterone recovery, do you alter the duration of ADT when using Leuprorelin (GnRH Agonist) vs relugolix (GnRH antagonist) in patients with intermediate or high-risk prostate cancer who received definitive radiation?
What adjuvant treatment would you offer a patient who underwent cystoprostatectomy for a muscle invasive bladder cancer and discovered to also have prostate cancer?
Do you recommend placement of a rectal spacer when delivering radiotherapy to the prostate in patients with oligometastatic prostate cancer?
What are your top takeaways from ASCO GU 2025?
What would your approach be in a man currently on treatment for high-risk prostate cancer with ADT who does not have castrate levels of testosterone?
Would you give immunotherapy after neoadjuvant gem-cis for bladder cancer if cystectomy is being postponed for months due to non-autoimmune/unrelated comorbidities?
How do you manage prostatic adenocarcinoma after a subtotal resection?
@Sushil Beriwal, could you share a paper or protoc...
This is the one I was referring to. It’s a s...